Skip to main content
SpringerLink
Log in

Rezum most cost effective option for LUTS in BPH

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. a cholestenone 5α-reductase inhibitor and an α-1 adrenergic receptor antagonist

  2. 2016 US dollars

Reference

  • Ulchaker JC, et al. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. ClinicoEconomics and Outcomes Research 2018: 29-43, No. 10, 29 Dec 2018. Available from: URL: https://doi.org/10.2147/CEOR.S148195

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rezum most cost effective option for LUTS in BPH. PharmacoEcon Outcomes News 795, 27 (2018). https://doi.org/10.1007/s40274-018-4665-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4665-0

Search

Navigation